MIR363

Summary

MIR363 (microRNA 363, HGNC:32023) is a microRNA gene on chromosome Xq26.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 574031 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32023
Approved symbol	MIR363
Name	microRNA 363
Location	Xq26.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-363, MIR-363
Ensembl gene	ENSG00000284499
Ensembl biotype	miRNA
Entrez	574031
RNAcentral	URS000075E6A6 — miRNA, 75 nt, 5 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384840

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384840 — 1 exons

Exon	Start	End
ENSE00001499847	134169378	134169452

Expression profiles

Bgee: expression breadth tissue_specific, 3 present calls, max score 69.20.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1139 / max 10.0660, expressed in 72 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
200576	0.1139	72

Top tissues by expression

3 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
dorsolateral prefrontal cortex	UBERON:0009834	69.20	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	67.29	gold quality
cerebellar hemisphere	UBERON:0002245	63.72	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• Data shsow that miR-363, miR-490, miR-137, miR-217 and miR-4792 were the top five significantly de-regulated miRNAs in uterine leiomyoma (ULM). (PMID:22446413)
• These data reveal a key role of miR-363-PDPN in HNSCC metastasis and support biological and clinical links between miR-363-PDPN and HNSCC. (PMID:23246488)
• negative regulator of Myc, revealing heretofore unappreciated role in hepatocarcinogenesis (PMID:23389829)
• c-Myc-regulated members of the miR-1792 and miR-106a363 clusters inhibit trophoblast differentiation by repressing GCM1 and CYP19A1. (PMID:23438603)
• These studies provide support for a pro-oncogenic role of the miR-106a~363 cluster in Ewing Sarcoma. (PMID:23638178)
• GRP-R-mediated tumorigenicity and increased metastatic potential in neuroblastoma are regulated, in part, by miR-335 and miR-363. (PMID:23806264)
• miR-363 plays an important role in the increment of gastric carcinogenesis via targeting MBP-1. (PMID:23975832)
• these results suggest that miR-363 regulates the transition from mitotic clonal expansion to terminal differentiation during adipogenesis in ADSCs, at least in part, by targeting E2F3. (PMID:24023010)
• Low miR-363 expression is associated with breast cancer. (PMID:24222117)
• miR-363-5p (previously termed miR-363*) was shown to modulate the expression of numerous EC-specific genes including some angiocrine factors. (PMID:24257019)
• miR-363 is a negative regulator of S1PR1 expression in hepatocellular carcinoma cells. (PMID:24631531)
• These data show that miR-363 negatively regulates the expression of HAND1 (PMID:24906886)
• miR-363-3p is an independent favorable prognostic factor in ACA (PMID:25230213)
• MiR-363 downregulated the Mcl-1 expression in breast cancer cells. (PMID:25416050)
• miR-363 levels were significantly decreased in hepatocellular carcinoma patients treated with cisplatin-based chemotherapy. MiR-363 levels were also lower in cisplatin-resistant HepG2 cells than in HepG2 cells. (PMID:26143754)
• miR-363 induces transdifferentiation of human kidney tubular cells via upregulation of TWIST/canonical WNT pathway. (PMID:26373846)
• miR-363 represses REG4 transcription via its suppression of GATA6. (PMID:26387746)
• the overexpression of miR-363 reduces cellular migration in head and neck cancer and reveal the biological relationship between miR-363, myosin 1b, and HPV-positive SCCHN. (PMID:26545583)
• MiR-363-3p showed low levels in GC tissues and cells. Enforced expression of miR-363-3p inhibited cell growth and migration of GC cells and vice versa. (PMID:26709677)
• Results showed that miR10b5p and miR3633p expression was downregulated while CREB1 expression was upregulated, and a negative correlation was found between miR10b5p and miR3633p and CREB1 expression in renal cell carcinoma. (PMID:26796749)
• Transfection of miRNA mimics for unexpressed members of the miR-106a-363 cluster (miR20b, miR-363-3p and miR-363-5p) exhibit an anti-proliferative effect on oral carcinoma cells, although likely mediated by different regulatory mechanisms. (PMID:27001184)
• our data reveal that overexpression of miR-363 correlates with the poor survival outcomes in patients with gastric cancer (PMID:27167197)
• These data demonstrated that the MALAT1/miR-363-3p/MCL-1 regulatory pathway controls the progression of gallbladder cancer. (PMID:27420766)
• Our results suggest that GATAl and miR-363 were involved in the regulation of hematopoiesis via the HIF-1alpha pathway in K562 cells under hypoxic condition. (PMID:27485543)
• Upregulation of miR363 promotes gliomas. (PMID:27495233)
• Data show that dendritic cells (DCs) induced Th17 cell differentiation through miR-363/Integrin alphav/TGF-beta pathway in patients with rheumatoid arthritis (RA). (PMID:28376277)
• Low miR363 expression is associated with lung adenocarcinoma. (PMID:28423618)
• Kaplan-Meier test revealed that low expression of hsa-miR-363-5p was associated with better overall survival of hepatocellular carcinoma patients. (PMID:28637446)
• The data presented here show that miR-363 is associated with HPV-positive/SPLI-negative tonsillar SCC. The prognostic value of miR-363 suggests a role in the assumed inverse correlation of smoking and SPLI-expression in the mode of HPV-infections in tonsillar but possibly also other head and neck squamous cells carcinoma. (PMID:29179866)
• Study provides evidence that mir-363 and its target S100A1 are under the regulatory function of FOXD2-AS1 aggravating nasopharyngeal carcinoma carcinogenesis. (PMID:29248577)
• miR-363-3p served as a tumor suppressor in OS tissues by targeting SOX4. (PMID:29471893)
• restoring the function of Runx2-targeting by miR-342 and miR-363 in multiple myeloma cells may afford a therapeutic benefit by preventing multiple myeloma progression.Implications: miR-342 and miR-363-mediated downregulation of Runx2 expression in multiple myeloma cells prevents multiple myeloma progression (PMID:29592898)
• plasma miR-363 and miR16 levels and the distribution between plasma and particle bound fractions in chronic lymphocytic leukaemia patients and normal subjects, were examined. (PMID:29739419)
• Colorectal cancer growth and metastasis were suppressed by the overexpression of miR-363-3p. (PMID:30021386)
• MiR-363-3p is an onco-miRNA which was significantly higher in glioma tissue. (PMID:30178846)
• miR-363 was associated with migration, cell adhesion and invasion, proliferation, apoptosis, alteration of endometrial cells in endometriosis and there were 139 potential target genes of miR-363 via microarray analysis. (PMID:30226573)
• Low miR363 expression is associated with gastric cancer proliferation and invasion. (PMID:30324628)
• There was a significant negative correlation between the expression levels of HMGA2 and miR3633p in liver cancer tissues. (PMID:30535489)
• miR-363-3p is induced by HIF-2alpha to promote the stemness of melanoma cells via inhibiting p21. (PMID:30784290)
• Study results revealed that MG-63 osteosarcoma cells contained low levels of miR-363, and that overexpression of miR-363 in MG-63 cells significantly inhibited the vitality, proliferation, and colony formation ability of the cells. Bioinformatics analysis and luciferase reporter assay indicated that PDZD2 was a direct target of miR-363. In vivo xenograft model further confirmed that miR-363 functioned as tumor suppressor. (PMID:30896877)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	mir363	ENSDARG00000081303
mus_musculus	Mir363	ENSMUSG00000070106

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.